Announcements Trials
Browse Landscape

Phase

Phase 2 20Phase 3 4Phase NA 2Phase 1/2 2Phase 4 1Phase 2/3 1Phase 1 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

HER2-positive Breast Cancer 1

Interventions

Propofol 9Sevoflurane 7Rituximab 7Specimen Handling 6Magnetic Resonance Spectroscopy 6Dexamethasone 6Trastuzumab 5Enoxaparin 5Bevacizumab 5Nivolumab 4Carboplatin 4Capecitabine 4Bupivacaine 4trametinib 3pirtobrutinib 3pembrolizumab 3dabrafenib 3atezolizumab 3apixaban 3Lenalidomide 3Indocyanine Green 3Gemcitabine 3Docetaxel 3Cyclophosphamide 3zanubrutinib 2venetoclax 2trastuzumab deruxtecan 2ribociclib 2polyethylene glycol 3350 2pertuzumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Recruiting × pyrotinib × Clear all
NCT06217185 2024-02-28

The Efficacy and Safety of Pyrotinib, Trastuzumab Combined With Taxanes in the Treatment of Trastuzumab-treated HER2+ Advanced Breast Cancer (ABC).

Hebei Medical University Fourth Hospital

Phase 4 Recruiting
100 enrolled
Breast

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡